This table shows the list known insiders, and is generated automatically from filings disclosed to the SEC. In addition to the names, most recent title, and director, officer, or 10% owner designation, we provide the latest disclosed holdings.
| Name | Shares | Options |
|---|---|---|
| Clarus Lifesciences III, L.P. | 1,930,395 | 0 |
| Flynn James E Through Deerfield Partners, L.P. | 1,853,967 | 0 |
| SHAFFER CHRISTY L | 1,605,240 | 0 |
| ORBIMED ADVISORS LLC | 562,500 | 0 |
| Guerard Frederic | 79,143 | 337,500 |
| BREUIL ROBERT S | 43,989 | 119,250 |
| Zamiri Parisa | 24,377 | 112,500 |
| 0 | 0 | |
| Salain Daniel | 0 | 0 |
| Sauer Dirk | 0 | 80,000 |
| EASTLAND JULIA MARIE | 0 | 0 |
| ACKERMANN CHRISTINA | 0 | 0 |
| Cagle Gerald D. | 0 | 0 |
| BJERKHOLT ERIC | 0 | 0 |
| Flynn James E Through Deerfield Private Design Fund III, L.P. | 0 | 0 |
| Flynn James E Through Deerfield Healthcare Innovations Fund, L.P. | 0 | 0 |
| Keyoung Hansoo Michael | 0 | 0 |
While Insider sales are normal part of tax harvesting and is part of compensation of executives - A large number of transactions would indicate that the management isnt convinced that the price will go up and hence reducing their holding. This would be a possible indicator or fall in price
| Name | Shares | Price | Date |
|---|---|---|---|
| BREUIL ROBERT S | 2,188 | 1.25 | 2022 Mar 31 |
Insider buys arent usual, since it indicates a high conviction by the management that they believe the price will go up eventually. Usually a good sign that investors should consider this as a factor to purchase a stock, especially if the current SP is lower than the price the management bought these at. The table below doesnt include any Stock Options or RSUs. They're just open market purchases by the insiders.
| Name | Shares | Price | Date |
|---|